HIV and TB Flashcards

1
Q

Impact of cART in children

A
  • immunological preservation and restoration
  • improved growth
  • prevent adverse neurocognitive deficits
  • reduction in infectious complications
  • preservation of vaccine-induced responses
  • reversal of organ-specific complications
  • slow/arrest the progression to AIDS
  • decreased risk for death/ prolong life expectancy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Criteria for fast-tracking cART (within 7 days of HIV diagnosis)

A
  • children <1 year
  • CD4 <15% or <200cell/ul
  • WHO stage 4
  • MDR/XDR TB
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Social criteria for cART

A

Mandatory
- indentifiable adult who is able to administer medication

Desirable
- demonstrated reliability of caregiver
- previous record of adherence
- ability to attend an antiretroviral treatment centre regularly
disclosure to another adult in the same house

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Common antiretrovial agents

A
  • NRTIs (abacavir, lamivudine, emtricitabine)
  • NtRTIs (tenofovir)
  • NNRTIs (neviropine, efavirenz)
  • PIs (lopinavir/ritonavir)
  • Integrase inhibitors (reltegravir)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Preferred 1st line regimen fo age <4 weeks

A
  • AZT
  • 3TC
  • NVP
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Preferred 1st line regimen for age 4 weeks-3 years

A
  • ABC
  • 3TC
  • LPV/r
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Preferred 1st line treatment for age 3-15

A

ABC
3TC
EFV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Preferred 1st line treatment for age 15-20

A

FDC

TDF
3TC
EFV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How often does VL need to be measured?

A
  • routine monitoring at 6 months and 12 months after starting cART
  • then every 12 months
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

When is VL suppressed?

A

if <50 copies/ml

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Causes of an unsuppressed VL

A
  • infection
  • poor adherence
  • incorrect dosing
  • poor absorption and reduced bioavailability
  • adverse drug interactions
  • drug resistance
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Factors impacting adherence

A
  • socio-demographic factors
  • inadequate counselling and education
  • care-giver factors
  • complex ARV regimen
  • side effects
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How to improve adherence

A
  • education/ counselling
  • patient feedback
  • support groups
  • simplify medication
  • manage side effects
  • provide tools
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

When is viral resistance testing done?

A
  • usually done after failing a PI-containing regimen
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Principles of treating drug-susceptible TB

A
  • combo therapy
  • short-course regimens comprising both bactericidal and sterilizing activity
  • intensive phase achieves rapid reduction of organism load
  • continuation phase ensure effective eradication of persistent bacilli
  • optimise adherence and minimise adverse effects
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Drugs used for susceptible TB

A
  • Isoniazid
  • Rifampicin
  • Pyrazinamide
  • Ethambutol
  • Ethionamide
17
Q

Genes conferring RIF resistance

A

rpoB

18
Q

Genes conferring INH resistance

A
  • katG
  • inhA
  • ahpC
19
Q

Definition of MDR-TB

A

Resistance to both INH and RIF

20
Q

Definition of pre-XDR-TB

A

Resistance to INH and RIF and either a fluoroquinolone or a second-line injectible

21
Q

Definition of XDR-TB

A

Resistance to INH and RIF as well as any fluoroquinolone and any of the second-line anti-TB injectable drugs

22
Q

Examples of injectable drugs

A
  • Streptomycin
  • Kanamycin
  • Amikacin
23
Q

Examples of Fluroquinolones

A
  • Levofloxacin

- Moxifloxacin

24
Q

Oral 2nd line drugs

A
  • ethionamide

- terizidone

25
Q

Manifestations of IRIS

A
  • swinging fever
  • new/worsening lymphadenitis
  • new/worsening pulmonary infilrates and resp failure
  • new/worsening pleuritis, pericarditis, ascites
  • intracranial tuberculomas
  • TBM
  • disseminated skin lesions
  • hepatosplenomegaly
  • soft-tissue absecesses
26
Q

IRIS

A

Immune reconsitution inflammatory syndrome

27
Q

Indications of preventive therapy after TB exposure

A
  • all symptomatic children <5 years of age

- all HIV-infected children

28
Q

Preventive therapy for drug-susceptible TB contact

A

Isoniazid 1-mg/kg/day per os for 6 months

29
Q

Preventive therapy for MDR-TB contact

A
  • isoniazid 15-20mg/kg/day
  • ethambutol 20-25mg/kg/day
  • levofloxacin 15-20mg/kg/day

for 6 months